MMR vaccination and disease elimination: The finnish experience

Expert Review of Vaccines

Volumn 9, Issue 9, 2010, Pages 1045-1053

  Davidkin, Irja ^a   Kontio, Mia ^a   Paunio, Mikko ^b   Peltola, Heikki ^c  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b Sosiaali ja terveysministerio   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

elimination; measles; MMR vaccination; mumps; rubella

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ALLERGIC REACTION; ASEPTIC MENINGITIS; AUTISM; DRUG SAFETY; ENCEPHALITIS; EPIDEMIOLOGICAL DATA; FINLAND; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; GUILLAIN BARRE SYNDROME; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; IMMUNOGENICITY; MEASLES; MUMPS; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; REVIEW; RUBELLA; VACCINATION;

DISEASE OUTBREAKS; FINLAND; HUMANS; INCIDENCE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; RUBELLA; VACCINATION;

EID: 77956468863     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.99     Document Type: Review

References (61)

1. Peltola H, Karanko V, Kurki T et al. Rapid effect on endemic measles, mumps, and rubella of nationwide vaccination programme in Finland. Lancet 1(8473), 137-139 (1986).
2. Peltola H, Heinonen OP, Valle M et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N. Engl. J. Med. 331(21), 1397-1402 (1994).
3. Paunio M, Virtanen M, Peltola H et al. Increase of vaccination coverage by mass media and individual approach: intensifed measles, mumps, and rubella prevention program in Finland. Am. J. Epidemiol. 133(11), 1152-1160 (1991).
4. Leino T, Koskenniemi E, Saranpää P-R, Strömberg N, Kilpi T. The vaccination coverage continues top high. Suom Lääkäril (J. Finn. Med. Assoc.) 62(8), 739-743 (2007).
5. Paunio M, Peltola H, Valle M, Davidkin I, Virtanen M, Heinonen OP. Explosive school-based measles outbreak: intense exposure may have resulted in high risk, even among revaccinees. Am. J. Epidemiol. 148(11), 1103-1110 (1998).
6. Paunio M, Peltola H, Valle M, Davidkin I, Virtanen M, Heinonen OP. Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccine. J. Epidemiol. Community Health 53(3), 173-178 (1999).
7. Paunio M, Hedman K, Davidkin I et al. Secondary measles vaccine failures identifed by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol. Infect. 124(2), 263-271 (2000).
8. Davidkin I, Valle M, Peltola H et al. Etiology of measles-and rubella-like illnesses in measles, mumps, and rubella-vaccinated children. J. Infect. Dis. 178(6), 1567-1570 (1998).
9. Davidkin I, Jokinen S, Paananen A, Leinikki P, Peltola H. Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella. J. Infect. Dis. 191(5), 719-723 (2005).
10. Peltola H, Jokinen S, Paunio M, Hovi T, Davidkin I. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infect. Dis. 8(12), 796-803 (2008).
11. Koskiniemi M, Vaheri A. Effect of measles, mumps, rubella vaccination on pattern of encephalitis in children. Lancet 1(8628), 31-34 (1989).
12. Ukkonen P. Rubella immunity and morbidity: impact of different vaccination programs in Finland 1979-1992. Scand. J. Infect. Dis. 28(1), 31-35 (1996).
13. Peltola H, Davidkin I, Valle M et al. No measles in Finland. Lancet 350(9088), 1364-1365 (1997).
14. Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP. Mumps and rubella eliminated from Finland. JAMA 284(20), 2643-2647 (2000).
15. Progress in global measles control and mortality reduction 2000-2007. Wkly Epidemiol. Rec. 83 (49), 441-448 (2008).
16. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. Lancet 1(8487), 939-942 (1986).
17. Virtanen M, Peltola H, Paunio M, Heinonen OP. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics 106(5), E62 (2000).
18. Juntunen-Backman K, Peltola H, Backman A, Salo OP. Safe immunization of allergic children against measles, mumps, and rubella. Am. J. Dis. Child. 141(10), 1103-1105 (1987).
19. Patja A, Mäkinen-Kiljunen S, Davidkin I, Paunio M, Peltola H. Allergic reactions to measles-mumps-rubella vaccination. Pediatrics 107(2), E27 (2001).
20. Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatr. Infect. Dis. J. 19(12), 1127-1134 (2000).
21. Patja A, Paunio M, Kinnunen E, Junttila O, Hovi T, Peltola H. Risk of Guillain-Barre syndrome after measles-mumps-rubella vaccination. J. Pediatr. 138(2), 250-254 (2001).
22. Peltola H, Patja A, Leinikki P, Valle M, Davidkin I, Paunio M. No evidence for measles, mumps, and rubella vaccine-associated infammatory bowel disease or autism in a 14-year prospective study. Lancet 351(9112), 1327-1328 (1998).
23. Davidkin I, Valle M, Julkunen I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. Vaccine 13(16), 1617-1622 (1995).
24. Davidkin I, Valle M. Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts. Vaccine 16(20), 2052-2057 (1998).
25. Davidkin I, Peltola H, Leinikki P, Valle M. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Vaccine 18(27), 3106-3112 (2000).
26. Davidkin I, Jokinen S, Broman M, Peltola H. 25-year follow-up of measles, mumps and rubella antibodies in MMR vaccinated cohort. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington DC, USA, 25-28 October 2008.
27. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J. Infect. Dis. 197(7), 950-956 (2008).
28. Mauldin J, Carbone K, Hsu H, Yolken R, Rubin S. Mumps virus-specifc antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays. J. Clin. Microbiol. 43(9), 4847-4851 (2005).
29. Cohen BJ, Doblas D, Andrews N. Comparison of plaque reduction neutralisation test (PRNT) and measles virus-specifc IgG ELISA for assessing immunogenicity of measles vaccination. Vaccine 26(50), 6392-6397 (2008).
30. Jokinen S, Österlund P, Julkunen I, Davidkin I. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. J. Infect. Dis. 196(6), 861-867 (2007).
31. Bangor-Jones RD, Dowse GK, Giele CM, van Buynder PG, Hodge MM, Whitty MM. A prolonged mumps outbreak among highly vaccinated aboriginal people in the Kimberley region of Western Australia. Med. J. Aust. 191(7), 398-401 (2009).
32. Barskey AE, Glasser JW, LeBaron CW. Mumps resurgences in the United States: a historical perspective on unexpected elements. Vaccine 27(44), 6186-6195 (2009).
33. Dayan GH, Quinlisk MP, Parker AA et al. Recent resurgence of mumps in the United States. N. Engl. J. Med. 358(15), 1580-1589 (2008).
34. Brockhoff HJ, Mollema L, Sonder GJ et al. Mumps outbreak in a highly vaccinated student population, The Netherlands, 2004. Vaccine 28(17), 2932-2936 (2010).
35. Sugerman DE, Barskey AE, Delea MG et al. Measles outbreak in a highly vaccinated population, San Diego, 2008: role of the intentionally undervaccinated. Pediatrics 125(4), 747-755 (2010).
36. Chen TH, Kutty P, Lowe LE et al. Measles outbreak associated with an international youth sporting event in the United States, 2007. Pediatr. Infect. Dis. J. DOI: 10.1097/INF.0b013e3181dbaacf (2010) (Epub ahead of print).
37. Hahne S, te Wierik MJ, Mollema L et al. Measles outbreak, The Netherlands, 2008. Emerg. Infect. Dis. 16(3), 567-569 (2010).
38. Follin P, Dotevall L, Jertborn M et al. Effective control measures limited measles outbreak after extensive nosocomial exposures in January-February 2008 in Gothenburg, Sweden. Euro Surveill. 13(30), 18937 (2008).
39. Dayan GH, Ortega-Sanchez IR, LeBaron CW, Quinlisk MP. The cost of containing one case of measles: the economic impact on the public health infrastructure-Iowa, 2004. Pediatrics 116(1), E1-E4 (2005).
40. Das M, Pakarinen L, Ruotsalainen E et al. Imported measles cases in Finland-effective epidemiological action. Suom Lääkäril (J. Finn. Med. Ass.) 64(7), 597-600 (2009).
41. Dallaire F, De Serres G, Tremblay F W, Markowski F, Tipples G. Long-lasting measles outbreak affecting several unrelated networks of unvaccinated persons. J. Infect. Dis. 200(10), 1602-1605 (2009).
42. Davidkin I, Broman M, Koskela P, Jokinen S. Impact of MMR vaccinations on measles, mumps and rubella antibody levels in the Finnish population. Presented at: ESCV 2008 Clinical Virology Annual Meeting. Saariselkä, Finland, 12-15 March 2008.
43. Kremer JR, Schneider F, Muller CP. Waning antibodies in measles and rubella vaccinees-a longitudinal study. Vaccine 24(14), 2594-2601 (2006).
44. LeBaron CW, Forghani B, Beck C et al. Persistence of mumps antibodies after 2 doses of measles-mumps-rubella vaccine. J. Infect. Dis. 199(4), 552-560 (2009).
45. LeBaron CW, Forghani B, Matter L et al. Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. J. Infect. Dis. 200(6), 888-899 (2009).
46. Mossong J, O'Callaghan CJ, Ratnam S. Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine 19(4-5), 523-529 (2000).
47. Mossong J, Muller CP. Modelling measles re-emergence as a result of waning of immunity in vaccinated populations. Vaccine 21(31), 4597-4603 (2003).
48. Paunio M, Hedman K, Davidkin I, Peltola H. IgG avidity to distinguish secondary from primary measles vaccination failures: prospects for a more effective global measles elimination strategy. Expert Opin. Pharmacother. 4(8), 1215-1225 (2003).
49. Muscat M, Bang H, Wohlfahrt J, Glismann S, Molbak K. Measles in Europe: an epidemiological assessment. Lancet 373(9661), 383-389 (2009).
50. Orenstein WA, Papania MJ, Wharton ME. Measles elimination in the United States. J. Infect. Dis. 189(Suppl. 1), S1-S3 (2004)
51. Global measles mortality, 2000-2008. MMWR Morb. Mortal. Wkly Rep. 58(47), 1321-1326 (2009)
52. Global reductions in measles mortality 2000-2008 and the risk of measles resurgence. Wkly Epidemiol. Rec. 84(49), 509-516 (2009).
53. Johansen K, Sjödin M, Westrell-Oskarsson L, Arneborn M, Akerlind B, Forsgren M. [Rubella still a problem in Europe-important that pregnant women have an adequate protection]. Lakartidningen 101(49), 3994-3996, 3998-3999 (2004).
54. Leuridan E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. Br. Med. J. 340, C1626 (2010).
55. Johansen K, Lopalco P. Passive immunity against measles in infants: is there a need for policy changes in the European vaccination schedules? Euro Surveill. 12(9), E3-E4 (2007).
56. Roberts C, Porter-Jones G, Crocker J, Hart J. Mumps outbreak on the island of Anglesey, North Wales, December 2008-January 2009. Euro Surveill. 14(5) (2009).
57. Marin M, Quinlisk P, Shimabukuro T, Sawhney C, Brown C, Lebaron CW. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students-Iowa, 2006. Vaccine 26(29-30), 3601-3607 (2008).
58. Cortese MM, Jordan HT, Curns AT et al. Mumps vaccine performance among university students during a mumps outbreak. Clin. Infect. Dis. 46(8), 1172-1180 (2008).
59. Peltola H, Kulkarni PS, Kapre SV, Paunio M, Jadhav SS, Dhere RM. Mumps outbreaks in Canada and the United States: time for new thinking on mumps vaccines. Clin. Infect. Dis. 45(4), 459-466 (2007).
60. Dayan GH, Rubin S. Mumps outbreaks in vaccinated populations: are available mumps vaccines effective enough to prevent outbreaks? Clin. Infect. Dis. 47(11), 1458-1467 (2008).
61. Peltola H, Jokinen S, Paunio M, Hovi T, Davidkin I. Virusyhdistelmä rokotuksen ensimmäiset 25 vuotta. Duodecim Med. J. 124(12), 1371-1380 (2008) (In Finnish).